-
BMRN Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
BioMarin Pharmaceutical (BMRN)
Company Profile
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 675.45 mm | 675.45 mm | 675.45 mm | 675.45 mm | 675.45 mm | 675.45 mm |
Cash burn (monthly) | 98.90 mm | 9.16 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 397.81 mm | 36.86 mm | n/a | n/a | n/a | n/a |
Cash remaining | 277.64 mm | 638.59 mm | n/a | n/a | n/a | n/a |
Runway (months of cash) | 2.8 | 69.7 | n/a | n/a | n/a | n/a |
13F holders | Current |
---|---|
Total holders | 546 |
Opened positions | 87 |
Closed positions | 91 |
Increased positions | 192 |
Reduced positions | 190 |
13F shares | Current |
---|---|
Total value | 12.12 tn |
Total shares | 176.92 mm |
Total puts | 1.27 mm |
Total calls | 2.00 mm |
Total put/call ratio | 0.6 |
Largest owners | Shares | Value |
---|---|---|
BlackRock | 22.62 mm | $1.59 tn |
Vanguard | 19.28 mm | $1.36 tn |
Primecap Management | 18.87 mm | $1.33 tn |
Dodge & Cox | 13.90 mm | $976.91 bn |
Capital Research Global Investors | 10.49 mm | $737.70 bn |
Viking Global Investors | 9.75 mm | $685.56 bn |
STT State Street | 8.82 mm | $620.18 bn |
AMP Ameriprise Financial | 4.28 mm | $300.95 bn |
Elliott Investment Management | 3.50 mm | $246.04 bn |
Geode Capital Management | 3.26 mm | $228.63 bn |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Nov 24 | Alexander Hardy | Common Stock | Payment of exercise | Dispose F | No | No | 66.03 | 14,295 | 943.90 k | 134,156 |
12 Nov 24 | Charles Greg Guyer | Common Stock | Sell | Dispose S | No | No | 66.3743 | 5,278 | 350.32 k | 68,909 |
31 Oct 24 | Alexander Hardy | Common Stock | Grant | Acquire A | No | No | 56.007 | 300 | 16.80 k | 148,451 |
31 Oct 24 | Charles Greg Guyer | Common Stock | Grant | Acquire A | No | No | 56.007 | 55 | 3.08 k | 74,187 |
30 Sep 24 | Gregory R Friberg | Common Stock | Grant | Acquire A | No | No | 0 | 7,870 | 0.00 | 29,060 |
30 Sep 24 | Gregory R Friberg | Common Stock | Grant | Acquire A | No | No | 0 | 21,190 | 0.00 | 21,190 |
30 Sep 24 | Gregory R Friberg | Stock Option (Right to Buy Common Stock) Common Stock | Grant | Acquire A | No | No | 70.29 | 49,850 | 3.50 mm | 49,850 |
13 Sep 24 | Henry J Fuchs | Common Stock | Payment of exercise | Dispose F | No | No | 84.9 | 12,098 | 1.03 mm | 185,074 |
30 Apr 24 | Henry J Fuchs | Common Stock | Grant | Acquire A | No | No | 68.646 | 300 | 20.59 k | 197,172 |